

CLAIMS

1. A method of treating a disorder or condition selected from: schizophrenia, anxiety disorders such as generalized anxiety disorder, panic disorder, posttraumatic stress disorder and phobias; psychotic episodes of anxiety: anxiety, agitation, excessive aggression, tension, or social or emotional withdrawal associated with psychosis; psychotic mood disorders such as severe major depressive disorder; mood disorders associated with psychotic disorders such as acute mania and depression associated with bipolar disorder, and mood disorders associated with schizophrenia; behavioral disturbances associated with mental retardation, autistic disorder, and conduct disorder; dementias such as dementias associated with Alzheimer's disease; drug-induced and neurodegeneration based dyskinesias; obsessive compulsive disorder; Tourette's syndrome; glaucoma; and ischemic retinopathy in a mammal, comprising administering to said mammal an amount of 6-chloro-5-(2-{4-[imino-(2-methylsulfanylphenyl)-methyl]-piperazin-1-yl}-ethyl)-1,3-dihydro-indol-2-one, or a pharmaceutically acceptable salt thereof, that is effective in treating such disorder or condition.
2. A method according to claim 1, wherein the disorder or condition being treated is schizophrenia.
3. A method according to claim 1, wherein the disorder or condition being treated is generalized anxiety disorder.
4. A method according to claim 1, wherein the disorder or condition being treated is a phobia.
5. A method according to claim 1, wherein the disorder or condition being treated is bipolar disorder.
6. A method according to claim 1, wherein the disorder or condition being treated is post traumatic stress disorder.
7. A method according to claim 1, wherein the disorder or condition being treated is a dementia.
8. A method according to claim 1, wherein the disorder or condition being treated is a behavioral manifestation of mental retardation.
9. A method according to claim 1, wherein the disorder or condition being treated is a behavioral manifestation of conduct disorder.
10. A method according to claim 1, wherein the disorder or condition being treated is a behavioral manifestation of autistic disorder.
11. A method according to claim 1, wherein the disorder or condition being treated is glaucoma.
12. A method according to claim 1, wherein the disorder or condition being treated is ischemic retinopathy.

EXPRESS MAIL NO. EF 321678382

13. A pharmaceutical composition for treating a disorder or condition selected from: schizophrenia, anxiety disorders such as generalized anxiety disorder, panic disorder, posttraumatic stress disorder and phobias; psychotic episodes of anxiety: anxiety, agitation, excessive aggression, tension, or social or emotional withdrawal associated with psychosis;
- 5 psychotic mood disorders such as severe major depressive disorder; mood disorders associated with psychotic disorders such as acute mania and depression associated with bipolar disorder, and mood disorders associated with schizophrenia; behavioral disturbances associated with mental retardation, autistic disorder, and conduct disorder; dementias such as dementias associated with Alzheimer's disease; drug-induced and neurodegeneration based
- 10 dyskinesias; obsessive compulsive disorder; Tourette's syndrome; glaucoma; and ischemic retinopathy in a mammal, comprising an amount of S-methyl-dihydro-ziprasidone, or a pharmaceutically acceptable salt thereof, that is effective in treating such disorder or condition, and a pharmaceutically acceptable carrier.

09073973-060401